Pimp lies again. The Japan trial was designed for Asians with hep B is very different than 94 US trial for caucasians with hep B. SCLN already confirmed the Japan 2003 trial results was successful and beat all currently approved treatments in Japan. The current phase 3 US trials are for Hep C which is a major problem in the USA.
Everyone knows that the trial from 10 years ago was conducted by Alpha 1 Biomedicals, Inc. ("Alpha 1") . The complaint was against the doctors leaking trial information hired by Alpha 1. SCLN was not involved as the licensee for China rights and had nothing to do with the doctors or the US trials in 94.
"The Commission's Complaint alleged that, in April 1994, Rangarao Panguluri, then a Fellow at Wayne State University in Detroit, Michigan, tipped a group of doctors practicing in Anaheim, California about the negative results of clinical tests of a new drug developed by Alpha 1 and licensed to SciClone.